University College, London

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

192

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

15 drugs in development

Approved1

Phase 34

Phase 23

Phase 14

By Therapeutic Area

top 6

Oncology

950%

Infectious Disease

422%

Neurology

16%

Ophthalmology

16%

Respiratory

16%

Immunology

16%

R&D Momentum

74/100

Pipeline Velocity

36/100

Trial Completion Rate

79/100

Pipeline Concentration

31/100

Pipeline Freshness

37/100

Strategic Signals

↗Active in Neurology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Recruiting

TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO

Jul 9, 2026

Recruiting

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Jul 3, 2026

Enrolling by invitation

Identification of Imaging Biomarkers and Predictive Modelling of Proliferative Vitreoretinopathy Using Deep Learning.

Earlier

Jun 24, 2026TrialEAT-UP - Extended Antibiotic Treatment in Chronic UTI Patients; a Phase II Safety and Efficacy Trial

Jun 24, 2026TrialA Series of N-of-1 Randomised, Adaptive, Blinded, Placebo-Controlled Trials of Overnight In-Bedroom Air Filtration as Adjuvant Treatment in Reducing Inflammatory Biomarkers Among Survivors of Adult-Onset Cancer With Elevated C-Reactive Protein

Jun 24, 2026TrialPhase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients With Previously Untreated Mantle Cell Lymphoma

Mar 1, 2026TrialACTinium in Castrate-RESistant Prostate Cancer After LUTEtium

Nov 11, 2025TrialAnti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

1 more events

Nov 1, 2025TrialOptimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Immunology(1 drug)

—

Immunology(1 drug)

Infectious Disease(4 drugs)

—

Infectious Disease(4 drugs)

Neurology(1 drug)

—

Neurology(1 drug)

Oncology(9 drugs)

—

Oncology(9 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(1 drug)

—

Unknown / Other(1 drug)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)